Medical Communications

The British Medical Journal, after its own investigation, found that Janssen knew early into the Phase III trial, known as …

Novo Nordisk, headquartered in Bagsvaerd, Denmark, has taken the decision to lose 1,000 of its workforce from a total global …

Bayer has announced that its Eylea (aflibercept) drug has received a final recommendation from NICE for the treatment of visual …

German pharma firm Merck has appointed Isabel De Paoli to the position of chief science officer in addition to her …

Leading pharmaceutical provider PCI Pharma Services will bring its expertise to the stage at CPHI Worldwide (Barcelona, October 4-6 2016) …

German pharma firm Merck has appointed Isabel De Paoli to the position of chief science officer in addition to her …

The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of Alexion Pharmaceutical’s Strensiq …

It’s Friday (and print day for the Pharmafocus October edition!) and its been a pretty explosive week, from new and …

Lundbeck’s experimental idalopirdine has failed to meet its primary endpoint in its first Phase III trial in the treatment of …

Danish pharma firm Novo Nordisk has announced its intention to provide insulin at discounted prices to the world’s poorest nations …

Novartis has announced that its cancer drug Zykadia (ceritinib) has achieved positive results in its Phase III clinical trial investigating …

Cambridge-based Artios Pharma has officially launched after raising £25 million in series A financing from US and European life science …

A historic UN declaration to fight drug-resistant infection across the globe has been signed by 193 countries at the United …

Gilead has put the brakes on a Phase II/III study of its anti-MMP9 antibody GS-5745 for the treatment of ulcerative …

AstraZeneca is no longer seeker European approval for its oral multi-VEGF receptor inhibitor cediranib for treatment of ovarian cancer after withdrawing …